Every round on record, with the sources behind each and the investors on them.
CNS Innovative Drug Developer
synphatec.comShanghai, ChinaBiotechFounded 2021
2 sources · checked 2 times, last 51m ago
Source 2 says investors were not disclosed, but Source 1 specifically identifies the lead, participants, and existing shareholders providing additional support; Source 1 therefore wins.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $50M | 2026-09-28 | Decheng Capital | 2 outlets. #13 in Trending |
2 sources · checked 2 times, last 51m ago [ VERIFIED · CORRECTED ] read against 2 sources Source 2 says investors were not disclosed, but Source 1 specifically identifies the lead, participants, and existing shareholders providing additional support; Source 1 therefore wins. | ||||
Synphatec is a neuroscience biotechnology company developing CNS medicines for psychiatric and neurodegenerative disorders, including depression and Alzheimer's disease.
Synphatec is pursuing CNS treatments for major unmet needs in depression and Alzheimer's disease, including a rapid-acting antidepressant aimed at improving on the safety limitations of existing NMDA-receptor therapy and a gene-therapy approach intended to inhibit beta-amyloid production at its source. Its latest Series A financing of over $50 million is earmarked for clinical development of SP-101 and SP-201, optimization of the i-NaS and SynX platforms, and expansion of its innovative pipeline.
Checked against 8 sources today